Limitations in the Use of Combined Gonadotropin Releasing Hormone Analog and Human Menopausal Gonadotropin for In Vitro Fertilization

In: Advances in Assisted Reproductive Technologies · 1990 · pp. 17–29 · doi:10.1007/978-1-4613-0645-0_2 · W105246695
book-chapter OA: closed CC0
Full text JSON View on OpenAlex View at publisher
AI-generated summary by claude@2026-06+body, 2026-06-07

Combined gonadotropin-releasing hormone analog and human menopausal gonadotropin use in IVF is limited by high cancellation rates (20-40%) mainly due to premature luteinizing hormone surges.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text

The paper discusses ovarian stimulation in IVF, focusing on the combined use of a gonadotropin-releasing hormone (GnRH) analog and human menopausal gonadotropin, with attention to premature LH surges as a major cause of cycle cancellation. It states that while stimulation protocols are tailored to patients’ hormonal status, 20–40% of patients are cancelled before ovum pick-up due mainly to premature LH surge, implying important limitations in achieving consistent ovarian control with this approach. A key caveat is that no single agent or dosage is optimal for all patients, so results depend on individual hormonal milieu and protocol adjustment rather than a universally effective regimen. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 6,327 characters · extracted from oa-doi-fallback · 3 sections · click to expand

Abstract

Ovarian stimulation is an important step in in vitro fertilization (IVF) therapy which has had a profound impact upon the success or failure of the whole procedure. It is now recognised that no single ovarian stimulation agent or dosage is optimal for all patients and that stimulation should be tailored and adjusted to best suit the patient’s own hormonal status. However, as with every stimulation protocol, 20% to 40% of the patients are cancelled before ovum pick-up mainly due to premature Luteinizing Hormone (LH) surge. Preview Unable to display preview. Download preview PDF. Similar content being viewed by others

References

Benadiva, C., Ben-Rafael, Z., Strauss, J.F., Mastroianni, L., and Flickinger G.L., 1988, Ovarian response of individuals to different dose of human menopausal gonadotropin, Fertil. Steril., 49:997. Ben-Rafael, Z., Dor, J., Mashiach, S., Blankstein, J., Lunenfeld B., and Serr D.M., 1983, Abortion rate in pregnancies following ovulation induced by human menopausal gonadotropin/ human chorionic gonadotropin, Fertil Steril 39: 157. Ben-Rafael, Z., Mastroianni, L., Strauss, J.F., and Flickinger G.L., 1986, Differences in ovarian stimulation in human menopausal gonadotropin treated women may be related to follicle stmulating hormone accumulation., Fertil Steril. 46: 486. Ben-Rafael, Z., Mastroianni, L., Meloni, F., Lee M.S., and Flickinger G.L., 1986, Total estradiol, free estradiol, sex hormone-binding globulin, and the fraction of estradiol bound to sex hormone binding globulin in human follicular fluid, J. Clin. Endocrinol. Metab., 63: 1106. Bider, D., Kokia, E., Lipitz, S., Blankstein, J., Mashiach, S, and Ben-Rafael, Z., Failure to improve ovarian response by combined GnRH agonist and gonadotropin therapy. (Submitted). Defazio J., Meldrum, D.R., Lu, J.K.H., Vale W.W., Rivier J.E., Judd, H.L., and Chang R.J., 1985, Acute ovarian response to long acting agonist of gonadotropin releasing hormone in ovulatory women and women with polycystic ovarian disease, Fertil. Steril., 44:453. Fleming, R., Haxton, M.J., Hamileton, M.P.R., McCune, G.S. Black, W.B., Macnaughton, M.C., and Coutts, J.R.T., 1985, Successful treatment of infertile women with oligomenorrhea using a combination of LHRH agonist and exogenous gonadotropins, Br. J. Obstet. Gynecol 2: 368. Fleming, R., and Coutts, J.R.T.,1986, Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropins suppression, Fertil. Steril., 45: 226. Kenigsberg D., Littman, B.A., and Hodgen G.D., 1986, Induction of ovulation in primate models. Endocrine reviews, 7: 34. Lemay, A., Sandow, J., Quisnel, G., Bergeron, J., and Merat, P., 1988 Escape from down regulation of pituitary ovarian axis following decreased infusion of luteinizing hormone releasing hormone agonist, Fertil. Steril., 49: 802. Mashiach, S., Dor, J., Goldenberg, M., Shalev, J., Blankstein, J., Rudak, E., Shoam, Z., Finelt, Z., Nebel, L., Goldman, B., and Ben-Rafael, Z., 1988, Protocols for induction of ovulation: The concept of programmed cycles, in: In vitro fertilization and other assisted reproduction, H.W. Jones, Jr. and C. Schrader., Eds., Annals. of N.Y. Acad. Sci., 541: 37. Popkin, R., Bramley, T.A., Currie, A., Shaw, R.W., Baird, D.T., Fraser, H.M. 1983, Specific binding of luitenising hormone releasing hormone to human luteal tissue. Biochem. Biophys. Res. Commun., 114:750. Radwanska, E., Rawlins, R.G., Turmmon, I., Maclin, V., Binor, Z., Damowski, W.P., 1988, Successful use of gonadotropin-releasing hormone agonist leuprolide for in vitro fertilization in a patient with polycystic ovarian disease and infertility unresponsive to standard treatment, Fertil. Steril. A 9: 356. Sandow, J., 1983, Clinical applications of LHRH and its analogues, Clin. Endocrinol., 18: 571. Sheehan, K.L, Casper, R.F, Yen, S.S.C., 1983, Induction of luteolysis by luteinizing hormone releasing factor (LRF) agonist: Sensitivity, reproducibility, and reversibility, Fertil. Steril., 37:209. Smith, E.M., Anthony, F.W., Gadd, S.C, Mosson., G.M., 1989, Trial of support treatment with human menopausal gonadotropin in the luteal phase after treatment with buserelin and human menopausal gonadotropin in women taking part in an in vitro fertilisation programme, BMJ., 298:1483. Stucky, B.G.A., Klogh E.G., Pullan P.T., Beilby J.A., Thompson, R.J., and Evans O.V., 1987, Continous gonadotropin-releasing hormone for ovulation induction in polycystic ovarian disease, Fertil. Steril., 48:1055. Testart, J., Forman, R., Belaish-Alart, J.C., Volante, M., Hazut, A., Strub, N., and Frydman, R., 1989, Embryo quality and uterine receptivity in in vitro fertilization cycles with or without agonists of gonadotropin releasing hormone, Human. Reprod., 4:198. Torode, H.W., Porter, P.N., Vaughan, J.I., Saunders D.M., 1987, Luteal phase support after in vitro fertilisation: A trial and rationale for selective use, Clinc. Reprod. Fertil., 5:255. Wildt, L., Diedrich, K., Van der Ven, H., Hasani, S. Al., Huber, H., and Klasen, R., 1986, Ovarian hyperstimulation for in-vitro fertilization controlled by GnRH agonist administered in combination with human menopausal gonadotropin, Human. Reprod 1:15. Zeleznik, A.J., and Kubik C.J., 1986, Ovarian response in Macaques to pulsatile infusion of follicle-stimulating hormone (FSH) and luteinizing hormone: Increased sensitivity of maturing follicle to FSH, Endocrinology, 119:2025. Author information Authors and Affiliations Editor information Rights and permissions Copyright information © 1990 Plenum Press, New York About this chapter Cite this chapter Ben-Rafael, Z. et al. (1990). Limitations in the Use of Combined Gonadotropin Releasing Hormone Analog and Human Menopausal Gonadotropin for In Vitro Fertilization. In: Mashiach, S., Ben-Rafael, Z., Laufer, N., Schenker, J.G. (eds) Advances in Assisted Reproductive Technologies. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0645-0_2 Download citation DOI: https://doi.org/10.1007/978-1-4613-0645-0_2 Publisher Name: Springer, Boston, MA Print ISBN: 978-1-4612-7907-5 Online ISBN: 978-1-4613-0645-0 eBook Packages: Springer Book Archive

Keywords

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (20)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK